Sarepta Therapeutics (SRPT) Non-Current Assets (2010 - 2026)

Sarepta Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $869.1 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 15.86% year-over-year to $869.1 million; the TTM figure through Mar 2026 stood at $3.5 billion (down 2.88% YoY), while the FY2025 annual figure was $811.8 million, down 8.76% from the prior year.
• Non-Current Assets was $869.1 million for Q1 2026 at Sarepta Therapeutics, up from $811.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $1.0 billion in Q1 2025 to a low of $525.2 million in Q1 2022.
• Historically, Non-Current Assets has averaged $737.3 million across 5 years, with a median of $740.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Non-Current Assets surged 38.81% in 2024, then fell 15.86% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $570.5 million in 2022, then advanced by 20.11% to $685.2 million in 2023, then rose by 29.84% to $889.7 million in 2024, then declined by 8.76% to $811.8 million in 2025, then gained by 7.06% to $869.1 million in 2026.
• The last three Non-Current Assets figures came in at $869.1 million (Q1 2026), $811.8 million (Q4 2025), and $771.1 million (Q3 2025), per Business Quant data.